Anti-Her2 Antibody-Drug Conjugates in: September 2016 R&D and Business Tracker for Antibody-Drug Conjugates

  • ID: 3940072
  • Report
  • Region: Global
  • 22 Pages
  • La Merie Publishing
1 of 2

This pdf report contains information about Antibody-Drug Conjugates (ADCs) released during the month of September 2016. This issue forms part of the subscription service R&D and Business Tracker for Antibody-Drug Conjugates which is listed in the "also available" below.

Featured presentations of September 2016 include the pipeline of Her2-targeted antibody-drug conjugates, the profile of Swiss biotech NBE Therapeutics and the profile of anti-Her2 antibody-drug conjugate MEDI4276 from AstraZeneca.

The September 2016 issue of our R&D and Business Tracker service about antibody-drug conjugates contains:

R&D and Technology Tracker:

- Pipeline changes
- Regulatory news
- Technology validations
- Manufacturing news

Business Tracker for:

- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing

Clinical Trial Tracker:

- Scientific Publication Tracker
- Featured ADC Profile: MEDI4276
- Featured Company Profile: NBE Therapeutics
- Featured Target Pipeline: Anti-Her2 Antibody-Drug Conjugates

Information about the anti-Her2 ADC pipeline is provided in a tabular format and fully referenced.

Methodology:

Information released during the previous month is retrieved from a variety of sources including corporate press releases and statements, quarterly company business reports, SEC filings, company presentations, company websites, interviews, webcasts, journal articles, scientific abstracts and reviews, relevant scientific meetings, clinical trial databases, and proprietary database. Relevant information is presented in textual and tabular formats with disclosure of scientific references or by a hyperlink leading to the source of information.

Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Adroll
adroll